Читать книгу Recent Advances in Dialysis Therapy in Japan - Группа авторов - Страница 49

1Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296–1305.

2Levin A, Singer J, Thompson CR, Ross H, Lewis M: Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996;27:347–354.

3Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Prognostic implications of echocardiography determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;332:1561–1566.

4Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE: Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 2000;11:912–916.

5Jari AL, Sudhir K, Jaakko E, Matti H, Jukka TS: Left atrium size and the risk of cardiovascular death in middle-aged men. Arch Intern Med 2005;165:1788–1793.

6Takeichi N, Fukuda N, Tamura Y, Oki T, Ito S: Relationship between left atrium function and plasma level of atrial natriuretic peptide in patients with heart disease. Cardiology 1998;90:13–19.

7Lang RM, Bierig M, Devereux RB, Flachskampf FA: Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440–1463.

8Devereux RB, Alonso DR, Lutas EM: Echocardiographic assessment of left ventricular hypertrophy. Comparison to necropsy findings. Am J Cardiol 1986;57:450–458.

9Harnett JD, Murphy B, Collingwood P, Purchase L, Kent G, Parfrey PS: The reliability and validity of echocardiographic measurement of left ventricular mass index in hemodialysis patients. Nephron 1993;65:212–214.

10Io H, Matsumoto M, Okumura K, Sato M, Masuda A, Furukawa M, Nohara N, Tanimoto M, Kodama F, Hagiwara S, Gohda T, Shimizu Y, Tomino Y: Predictive factors associated with left ventricular hypertrophy at baseline and in the follow-up period in non-diabetic hemodialysis patients. Semin Dial 2011;24:349–354.

11Io H, Ro Y, Sekiguchi Y, Shimaoka T, Inuma J, Hotta Y, Aruga S, Inami Y, Sato M, Kobayashi T, Masuda A, Kaneko K, Hamada C, Ohtaki E, Horikoshi S, Tomino Y: Cardiac function and structure in longitudinal analysis of echocardiography in peritoneal dialysis patients. Perit Dial Int 2010;30:353–361.

12Foley RN, parfrey PS, Morgan J, et al: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000;58:1325–1335.

13Jeren-Strujic B, Raos V, Jeren T, Horvatin-Godler S: Morphologic and functional changes of left ventricle in dialyzed patients after treatment with recombinant human erythropoietin (r-HuEPO). Angiology 2000;51:131–139.

14Levin A, Djurdjev O, Barrett B, Burgess E, Carlisle E, Ethier J, Jindal K, Mendelssohn D, Tobe S, Singer J, Thompson C: Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. Am J Kidney Dis 2001;38:1398–1407.

15Chan CT, Floras JS, Miller JA, Richardson RMA, Pierratos A: Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 2002;61:2235–2239.

16Furukawa M, Io H, Tanimoto M, Hagiwara S, Horikoshi S, Tomino T: Predictive factors associated with the period of time before initiation of hemodialysis in CKD stages 4 and 5. Nephron Clin Pract 2011;117:c341–c347.

17Spoto B, Testa A, Parlongo RM, Tripepi G, Trischitta V, Mallamaci F, Zoccali C: Insulin resistance and left ventricular hypertrophy in end-stage renal disease: association between the ENNP1 gene and left ventricular concentric remodeling. Nephrol Dial Transplant 2012;27:661–666.

18Matsumoto M, Io H, Furukawa M, Okumura K, Masuda A, Seto T, Takagi M, Sato M, Nagahama L, Omote K, Hisada A, Horikoshi S, Tomino Y: Risk factors associated with increased left ventricular mass index in chronic kidney disease patients evaluated using echocardiography. J Nephrol 2012;25:794–801.

19Moe SM, Duan D, Doehle BP, O’Neill KD, Chen NX: Uremia induces the osteoblast differentiation factor Cbfal in human blood vessels. Kidney Int 2003;63:1003–1011.

20Testa A, Mallamaci F, Benedetto FA, Pisano A, Tripepi G, Malatino L, Thadhani R, Zoccali C: Vitamin D Receptor (VDR) gene polymorphism is associated with left ventricular (LV) mass and predicts left ventricular hypertrophy (LVH) progression in end-stage renal disease (ESRD) patients. J Bone Miner Res 2010;25:313–319.

21Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D (CHOIR Investigators): Correction of anemia with epoetin alpha in chronic kidney disease. N Engl J Med 2006;355:2085–2098.

22Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A (CREATE Investigators): Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071–2084.

23Okumura K, Io H, Matsumoto M, Seto T, Takagi M, Masuda A, Furukawa M, Nagahama L, Omote K, Hisada A, Hamada C, Horikoshi S, Tomino Y: Predictive factors associated with change rates of LV hypertrophy and renal dysfunction in CKD patients. Clin Nephrol 2013;79:7–14.

24Aqabiti RE, Muiesan ML, Salvetti M: New approaches to the assessment of left ventricular hypertrophy. Ther Adv Cardiovasc Dis 2007;1:119–128.

Hiroaki Io, MD, PhD

Department of Nephrology

Juntendo University Nerima Hospital

3-1-10 Takanodai, Nerima-ku, Tokyo 177-8521 (Japan)

E-Mail hiroaki@juntendo.ac.jp